SPEVIGO
Active substance: spesolimab
INJECTION · SPESOLIMAB 300 mg/1
United StatesActive
Marketing holder: Boehringer Ingelheim Pharmaceuticals, Inc.
Verified 2026-10-09 · openFDA NDC
Analogues in other countries- Source: openFDA NDC
- Countries with the substance registered: 2
Composition
- SPESOLIMAB · 300 mg/1
Analogues by country
Products with the same active substance registered in other countries.
| Country | Products |
|---|---|
| EU 1 |
|
Import and control
Control by country
- United Statesprescription only
Source: openFDA NDC · record 01a1208c-326f-7104-a164-8b88a2e7cb3e,01a1208c-32b3-7c03-9730-ba1eae7d6b58,01a1208d-2ee6-75e4-aaef-0998e54ee0bf,01a1208f-1d23-7dc2-bf9c-61b4add100ed,01a12093-92ce-74d0-96e3-9b1562efa03e;count=6 · valid from 2026-10-09 · verified 2026-10-09
Registration
- Registration number
- 0597-7705
- Registration status
- Active
- Dispensing
- Prescription only
- Route
- INTRAVENOUS
Sources
- product · openFDA NDC · 0597-7705 · Verified 2026-10-09 · open in source
- registration_status · openFDA NDC · 0597-7705 · Verified 2026-10-09 · open in source
- ingredients.0 · openFDA NDC · 0597-7705 · Verified 2026-10-09 · open in source